FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Enhancing Patient Understanding of Perianal Fistula MRI Findings Using ChatGPT: A Randomized, Single Centre Study. PMID 41515567 · Diagnostics (Basel) · 2025-Dec-25 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life of patients undergoing active surveillance versus standard surgery for oesophageal cancer (SANO trial). PMID 41591326 · Br J Surg · 2025-Dec-24 The record is an original, randomized, oncology study in humans. However, it is excluded because: 1) The trial phase is not explicitly established as Phase III or II/III in the provided metadata; it is a stepped-wedge cluster-randomized trial. 2) The intervention is non-drug-only (active surveillance vs. surgery). 3) The primary endpoint is health-related quality of life, not a time-to-event efficacy endpoint. 4) The report is a quality-of-life analysis, not the primary efficacy report of the trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials. PMID 41448717 · BMJ Open · 2025-Dec-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Three-dimensional printing model-assisted single-port laparoscopic multiple myomectomy: a randomized controlled trial. PMID 41444772 · Sci Rep · 2025-Dec-24 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies. PMID 41437135 · Prostate Cancer Prostatic Dis · 2025-Dec-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial. PMID 41436191 · BMJ · 2025-Dec-23 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | confirmed 2 Figure · 4 Panel · risk visible |
| Pharmacogenomic, pharmacokinetic, and safety analysis of CYP3A4/CYP3A5 polymorphisms of midostaurin in patients with acute myeloid leukemia. PMID 41432755 · Eur J Clin Pharmacol · 2025-Dec-23 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML. PMID 41026969 · Blood Adv · 2025-Dec-23 The record describes a randomized Phase II/III trial (AML19) with drug intervention (midostaurin + gemtuzumab ozogamicin) and reports time-to-event efficacy endpoints (OS, EFS). However, the abstract and metadata do not explicitly confirm the trial phase as Phase III/IIIb or Phase II/III; it is described as a 'UK National Cancer Research Institute AML19 trial' and the deterministic review flags phase3 evidence as unclear. Since the phase cannot be definitively established from the provided information, the record is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study. PMID 40924923 · Blood Adv · 2025-Dec-23 The record describes a long-term extension study (LTE1) analyzing a subgroup of patients who transitioned from ibrutinib to zanubrutinib from the parent ASPEN Phase III trial. While the parent trial was a Phase III randomized trial with a drug intervention, this specific report is not the original primary result of that trial. Furthermore, it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR; the outcomes are safety and disease response rates. The analysis is explicitly noted as nonrandomized/ad hoc for this subgroup. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel. PMID 40862696 · Blood Adv · 2025-Dec-23 The study is excluded because it is not an oncology trial (it addresses a non-malignant hematologic condition) and its primary endpoint is quality of life, not a time-to-event efficacy measure. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel. PMID 40857358 · Blood Adv · 2025-Dec-23 The record describes a phase 3 trial of a gene-edited cell therapy for sickle cell disease, which is not an oncology/malignant neoplasm study. The primary focus is on health-related quality of life patient-reported outcomes, not a time-to-event efficacy endpoint. Additionally, the trial appears to be single-arm, not randomized. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Rationale and Study Design to Assess the Efficacy and Safety of Minocycline in Patients with Moderate to Severe Acute Ischaemic Stroke (EMPHASIS). PMID 40147820 · Stroke Vasc Neurol · 2025-Dec-23 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of Protein Intake on Training Response in Chronic Lung Disease. PMID 41515158 · Nutrients · 2025-Dec-22 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Skin cancer and hyperthermia and radiotherapy - SAHARA: study protocol for a multicenter, two-arm, open-label, randomized controlled phase II non-inferiority trial. PMID 41430304 · Trials · 2025-Dec-22 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness analysis of datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer. PMID 41430249 · Cost Eff Resour Alloc · 2025-Dec-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma. PMID 41429779 · Blood Cancer J · 2025-Dec-22 The report is an original results publication from a phase 2/3 trial in multiple myeloma, which is oncology, human, and involves a drug intervention. However, the abstract explicitly describes this as a 'subanalysis of the non-randomized phase 2 component,' which lacks randomization. Furthermore, the primary endpoint reported is renal response (a response rate), not a time-to-event efficacy endpoint such as OS, PFS, DFS, or Kaplan-Meier/HR analysis. The deterministic review signal for time-to-event is correctly false. Therefore, it does not meet the criteria for a definitive randomized trial with a time-to-event endpoint. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Efficacy and Safety of Traditional Chinese Medicine Qufenghuoxue Formula on Treating Peripheral Neuropathy Induced by Paclitaxel in Advanced Lung Cancer: A Randomized Clinical Trial. PMID 41428261 · Support Care Cancer · 2025-Dec-22 The study is an oncology RCT in humans with a drug intervention and is an original result report. However, it is excluded because the primary efficacy endpoint is not a time-to-event efficacy endpoint (like OS, PFS, DFS, etc.), but a proportion of CIPN relief and recovery time. The phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, and the hazard ratio presented is for a secondary outcome (dose reduction/cessation), not for a primary key efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Transcutaneous Auricular Vagus Nerve Stimulation Reduces Inflammatory Biomarkers after Large Vessel Occlusion Stroke: Results of a Prospective Randomized Open-Label Blinded Endpoint Trial. PMID 41428140 · Transl Stroke Res · 2025-Dec-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Understanding shared decision-making among patients with limited health literacy: a realist review protocol. PMID 41423643 · Syst Rev · 2025-Dec-22 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer. PMID 41186991 · JCI Insight · 2025-Dec-22 The record describes a preplanned biomarker analysis from the CARD trial (Phase IV per publication type). It is not the primary report of the Phase III trial results; it is a biomarker subgroup analysis. Therefore, it does not meet the inclusion criteria for a definitive Phase III trial primary result report with drug intervention and time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial. PMID 41423619 · Nat Commun · 2025-Dec-21 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 1 Figure · 2 Panel · risk visible |
| Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study. PMID 41423595 · Breast Cancer Res · 2025-Dec-21 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data. PMID 41423272 · J Immunother Cancer · 2025-Dec-21 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 2 Figure · 10 Panel · risk visible |
| Melatonin supplementation for quality of life in older patients with advanced cancer: a randomized controlled trial. PMID 41421991 · BMC Geriatr · 2025-Dec-20 The trial is a randomized controlled trial in oncology patients, but it does not meet key eligibility criteria. The phase is not specified as Phase III/IIIb or Phase II/III. The intervention is melatonin (a dietary supplement), not a drug. The primary endpoint is quality of life, and while survival is mentioned as a secondary objective, the results do not present a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) with Kaplan-Meier or HR analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| 177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study. PMID 41223345 · J Clin Oncol · 2025-Dec-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial. PMID 41037766 · J Clin Oncol · 2025-Dec-20 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 3 Panel · risk unclear |
| Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites. PMID 41600920 · Vaccines (Basel) · 2025-Dec-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Lessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus. PMID 41515918 · Int J Mol Sci · 2025-Dec-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The impact of early nutritional care intervention on gastrointestinal function, immune function and nutritional indicators in patients after radical surgery for esophageal cancer: A single-center, observational study. PMID 41431032 · Medicine (Baltimore) · 2025-Dec-19 Excluded due to lack of drug intervention and lack of time-to-event efficacy endpoint. The study is a randomized trial of nutritional care, not a drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cost and cost-effectiveness of attractive targeted sugar baits (ATSB) in the context of a phase III cluster randomized control trial in Western Province, Zambia. PMID 41420162 · Malar J · 2025-Dec-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| O04 Mission EB -mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: a randomised, double-blinded, placebo controlled, crossover trial. PMID 41412990 · Br J Dermatol · 2025-Dec-19 The record describes a Phase II crossover trial of a cell therapy (mesenchymal stromal cells) in pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a genetic disorder with cancer risk but not a primary malignancy trial. The main efficacy endpoints are disease severity scores, wound appearance, pain, itch, and quality of life, not time-to-event outcomes (OS, PFS, DFS, etc.). The abstract explicitly states 'Results will be discussed at the meeting', indicating this is a protocol or interim presentation without final results. The intervention is a cell product, not a conventional drug, and the phase is not Phase III/IIIb or definitive Phase II/III. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Reconstruction after distal gastrectomy and alkaline gastritis: a multi-center three-arm randomized trial comparing Billroth-II, Billroth-II Braun, and Uncut Roux-en-Y (SDR-02). PMID 41417990 · Int J Surg · 2025-Dec-18 This is a randomized Phase III trial in human gastric cancer, but the intervention is purely surgical (reconstruction methods) with no drug component. The primary endpoint is the incidence of bile reflux at 3 months (a categorical outcome), not a time-to-event efficacy endpoint. Therefore, it does not meet the drug intervention or time-to-event criteria. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial. PMID 41413453 · BMC Infect Dis · 2025-Dec-18 The study is a randomized, placebo-controlled Phase III trial of a drug (HPV vaccine) with an oncology indication (prevention of cervical neoplasia). However, the primary efficacy endpoint is the proportion developing CIN2+, a categorical outcome, not a time-to-event endpoint like OS, PFS, or DFS. No Kaplan-Meier curves, hazard ratios, or other time-to-event analyses are reported in the abstract. Therefore, it does not meet the required time-to-event efficacy endpoint criterion. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial. PMID 41413016 · Signal Transduct Target Ther · 2025-Dec-18 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Tolvaptan pharmacokinetics and pharmacodynamics in adolescents with autosomal dominant polycystic kidney disease. PMID 41407907 · Eur J Pediatr · 2025-Dec-18 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis. PMID 41406445 · N Engl J Med · 2025-Dec-18 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. PMID 41406444 · N Engl J Med · 2025-Dec-18 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Coagulation factor XI and coronary artery disease: is there room for factor XI inhibitors? PMID 41312611 · Pol Arch Intern Med · 2025-Dec-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer. PMID 41124204 · N Engl J Med · 2025-Dec-18 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial. PMID 40991848 · Blood · 2025-Dec-18 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 3 Figure · 8 Panel · risk unclear |
| LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL. PMID 40857670 · Blood · 2025-Dec-18 The abstract describes a biomarker/genetic analysis (LEF1 alterations) from Phase II/III T-ALL trial cohorts but does not report a primary or key secondary time-to-event efficacy endpoint (like OS, PFS, etc.) with Kaplan-Meier or HR results. It focuses on biological insights and treatment response associations, not definitive trial outcome data. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Fragility of Evidence for the Efficacy of Anti-Fracture Medications. PMID 40488289 · J Clin Endocrinol Metab · 2025-Dec-18 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Interrater reliability in the assessment of oral mucositis among patients receiving high-dose chemotherapy: a multicenter comparison between specialized dentists and registered nurses. PMID 41408611 · BMC Cancer · 2025-Dec-17 The report is a methodological sub-study (interrater reliability) from a Phase III oncology trial, not the primary efficacy analysis. It lacks a time-to-event efficacy endpoint and does not report original trial results for a drug intervention. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Associations and predictive value of weight-adjusted waist index for cardiovascular outcomes in type 2 diabetes: evidence from the ACCORD study. PMID 41408264 · Nutr J · 2025-Dec-17 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-term protection from naturally acquired immunity against hepatitis E virus reinfection. PMID 41407683 · Nat Commun · 2025-Dec-17 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study. PMID 41407426 · BMJ Open · 2025-Dec-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Ambulatory laparoscopic colorectal surgery management paradigm with initial experience: a prospective randomized clinical trial. PMID 41405332 · Int J Surg · 2025-Dec-17 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Recombinant human type-5 adenovirus (H101) combined with radiofrequency ablation versus traditional radiofrequency ablation for hepatocellular carcinoma ≤ 3 cm: a phase III randomized controlled trial. PMID 41403317 · Int J Surg · 2025-Dec-16 The record is a Phase III randomized trial in human oncology with a primary time-to-event efficacy endpoint (DFS) and a drug-containing intervention (H101). It reports original formal results. |
H
S
B
|
严格 v3 独有 | eligiblemodel_adjudicated_eligible | confirmed 2 Figure · 3 Panel · risk visible |
| Tegileridine for moderate-to-severe acute pain following abdominal surgery: A randomized, double-blind, phase 3 clinical trial. PMID 41365300 · Cell Rep Med · 2025-Dec-16 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome. PMID 41321238 · Circulation · 2025-Dec-16 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |